Median Technologies will participate to the annual conference 2017 of the ASCO, June 2-6, in Chicago,…

SOPHIA ANTIPOLIS, France, May 31, 2017 – Median Technologies, the Imaging Phenomics Company™, today announced its participation at the annual conference 2017 of the ASCO (American Association of Clinical Oncology), which will be held from 2 to 6 June at McCormick Place in Chicago, United States. The presentation of the exhibitors will be open from 3 to 6 June 2017.

Download the free guide
Boost your gains

Median Technologies will present on booth number 7113. The company will present its offer of solutions and services for the management of images in clinical trials, based on its two platforms, imaging, iBiopsy® and LMS (Lesion Management Solutions).

Median technologies will present its platform iBiopsy® for the first time in the framework of a conference in oncology. iBiopsy® (Imaging Biomarker Phenotyping System) is an innovative platform that combines biomarker imaging non-invasive imaging phénomique. This unique combination of science and technology is decisive in the context of predictive medicine and personalized medicine because it provides some indications both for the development of new therapies and for the establishment of treatment strategies are individualised. In particular, iBiopsy® enables the measuring of the disease and assess response to therapy without the use of biopsies, which are invasive procedures and costly.

The annual conference of the ASCO is the largest conference in oncology at a global level. It brings together each year more than 35,000 oncologists from all over the world as well as all representatives of the medical communities, scientists and industry involved in the field of oncology. More information on the annual conference of the ASCO :

About Median Technologies : Median Technologies provides solutions and services innovative imaging to advance health care for all. We exploit the power of the imaging phénomique to contribute to the emergence of new therapies and treatment strategies for patients. Our solutions, LMS for the management of the lesions and our imaging platform phénomique iBiopsy® allied to the expertise of our teams contribute to the discovery of new drugs and new diagnostic tools to monitor disease and assess the response of patients to their therapy.

Median Technologies helps biopharmaceutical companies as well as health professionals to bring new treatments to patients who need it, more accurately and faster, in a perspective of reducing overall costs of care. Thus, we contribute to a healthier world.

Established in 2002, based in Sophia Antipolis in France, with a subsidiary in the United States in Boston, the Median is labeled “innovative Company” by BPI Financing and is listed on the Alternext market of Euronext Paris. ISIN Code : FR0011049824 – MNEMO Code : ALMDT. Median is eligible for the PEA PME. The company is also labeled Pass French Tech Promotion in 2016-2017. Median Technologies has been awarded the Tech 40 2017 and is part of the index Tech 40 of EnterNext. Median is also a member of the network Bpifrance Excellence. More information on

Download the free guide
Boost your gains

Like this post? Please share to your friends:
Leave a Reply